JP2020502051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502051A5 JP2020502051A5 JP2019524067A JP2019524067A JP2020502051A5 JP 2020502051 A5 JP2020502051 A5 JP 2020502051A5 JP 2019524067 A JP2019524067 A JP 2019524067A JP 2019524067 A JP2019524067 A JP 2019524067A JP 2020502051 A5 JP2020502051 A5 JP 2020502051A5
- Authority
- JP
- Japan
- Prior art keywords
- arginine
- pharmaceutically acceptable
- acceptable salt
- bicyclic peptide
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 125
- 125000002619 bicyclic group Chemical group 0.000 claims description 93
- 150000001413 amino acids Chemical class 0.000 claims description 59
- 229940024606 amino acid Drugs 0.000 claims description 58
- 235000001014 amino acid Nutrition 0.000 claims description 58
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 54
- 229930064664 L-arginine Natural products 0.000 claims description 51
- 235000014852 L-arginine Nutrition 0.000 claims description 51
- 150000001875 compounds Chemical class 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 30
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 22
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 18
- 229930028154 D-arginine Natural products 0.000 claims description 17
- 229960005190 phenylalanine Drugs 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 230000002209 hydrophobic effect Effects 0.000 claims description 12
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 12
- 235000008729 phenylalanine Nutrition 0.000 claims description 12
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 9
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 9
- 229930182832 D-phenylalanine Natural products 0.000 claims description 9
- 239000004475 Arginine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 235000009697 arginine Nutrition 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 6
- 230000004850 protein–protein interaction Effects 0.000 claims description 6
- -1 N- alkyl Chemical group 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 125000001151 peptidyl group Chemical group 0.000 claims description 4
- 101100522280 Dictyostelium discoideum ptpA1-2 gene Proteins 0.000 claims description 3
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 claims description 3
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 3
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 101150006497 PTP-1 gene Proteins 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 102000034356 gene-regulatory proteins Human genes 0.000 claims description 3
- 108091006104 gene-regulatory proteins Proteins 0.000 claims description 3
- 101150098203 grb2 gene Proteins 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 210000000805 cytoplasm Anatomy 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 125000001165 hydrophobic group Chemical group 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 10
- 108010069514 Cyclic Peptides Proteins 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 102000001284 I-kappa-B kinase Human genes 0.000 description 4
- 108060006678 I-kappa-B kinase Proteins 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical class OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- DXJTZNDICCWSDR-UHFFFAOYSA-N 3,5-bis(sulfanylmethyl)benzoic acid Chemical group OC(=O)C1=CC(CS)=CC(CS)=C1 DXJTZNDICCWSDR-UHFFFAOYSA-N 0.000 description 1
- 101100347605 Arabidopsis thaliana VIII-A gene Proteins 0.000 description 1
- 101100025412 Arabidopsis thaliana XI-A gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022179784A JP7490735B2 (ja) | 2016-11-09 | 2022-11-09 | ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419781P | 2016-11-09 | 2016-11-09 | |
| US62/419,781 | 2016-11-09 | ||
| US201662425550P | 2016-11-22 | 2016-11-22 | |
| US62/425,550 | 2016-11-22 | ||
| US201662438141P | 2016-12-22 | 2016-12-22 | |
| US62/438,141 | 2016-12-22 | ||
| PCT/US2017/060881 WO2018089648A2 (en) | 2016-11-09 | 2017-11-09 | Di-sulfide containing cell penetrating peptides and methods of making and using thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022179784A Division JP7490735B2 (ja) | 2016-11-09 | 2022-11-09 | ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502051A JP2020502051A (ja) | 2020-01-23 |
| JP2020502051A5 true JP2020502051A5 (enExample) | 2020-12-03 |
| JP7175887B2 JP7175887B2 (ja) | 2022-11-21 |
Family
ID=62109979
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524067A Active JP7175887B2 (ja) | 2016-11-09 | 2017-11-09 | ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法 |
| JP2022179784A Active JP7490735B2 (ja) | 2016-11-09 | 2022-11-09 | ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022179784A Active JP7490735B2 (ja) | 2016-11-09 | 2022-11-09 | ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11351222B2 (enExample) |
| EP (1) | EP3538125A4 (enExample) |
| JP (2) | JP7175887B2 (enExample) |
| CN (2) | CN110114075B (enExample) |
| CA (1) | CA3043464A1 (enExample) |
| TW (1) | TWI781963B (enExample) |
| WO (1) | WO2018089648A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110114075B (zh) | 2016-11-09 | 2024-01-12 | 俄亥俄州国家创新基金会 | 含有二硫化物的细胞穿透肽及其制备和使用方法 |
| US11352394B2 (en) * | 2016-11-22 | 2022-06-07 | Ohio State Innovation Foundation | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof |
| US10913773B2 (en) * | 2016-11-22 | 2021-02-09 | Ohio State Innovation Foundation | Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha |
| US12410143B2 (en) | 2017-01-17 | 2025-09-09 | Michael David FORREST | Therapeutic inhibitors of the reverse mode of ATP synthase |
| BR112019028172A2 (pt) | 2017-07-13 | 2020-10-06 | Michael David Forrest | moduladores terapêuticos do modo reverso da atp sintase |
| CA3078504A1 (en) | 2017-10-04 | 2019-04-11 | Ohio State Innovation Foundation | Bicyclic peptidyl inhibitors |
| CN111447941B (zh) | 2017-10-27 | 2023-10-31 | 俄亥俄州国家创新基金会 | 用于细胞内递送装订肽的多肽缀合物 |
| US11793884B2 (en) | 2018-01-29 | 2023-10-24 | Ohio State Innovation Foundation | Cyclic peptidyl inhibitors of CAL-PDZ binding domain |
| WO2019148194A2 (en) | 2018-01-29 | 2019-08-01 | Ohio State Innovation Foundation | Peptidyl inhibitors of calcineurin-nfat interaction |
| TW201945014A (zh) | 2018-02-22 | 2019-12-01 | 美商安卓達治療股份有限公司 | 用於治療粒線體性神經胃腸腦病變之組合物及方法 |
| US11987647B2 (en) | 2018-05-09 | 2024-05-21 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
| EP3817776A4 (en) | 2018-07-02 | 2022-11-30 | Ohio State Innovation Foundation | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR RELEASE OF NUCLEIC ACIDS |
| US12391939B2 (en) | 2018-07-23 | 2025-08-19 | The Governors Of The University Of Alberta | Genetically-encoded bicyclic peptide libraries |
| WO2020195302A1 (ja) * | 2019-03-28 | 2020-10-01 | 株式会社カネカ | 細胞膜透過性環状ペプチド作製用リンカー分子、及びその利用 |
| CN110734474B (zh) * | 2019-11-29 | 2021-10-19 | 中山大学 | 一种抗菌肽的筛选方法及其应用 |
| EP4706689A2 (en) | 2019-12-19 | 2026-03-11 | Entrada Therapeutics, Inc. | Compositions for delivery of antisense compounds |
| US20230212235A1 (en) * | 2019-12-30 | 2023-07-06 | Ohio State Innovation Foundation | Looped proteins comprising cell penetrating peptides |
| WO2022065173A1 (ja) * | 2020-09-23 | 2022-03-31 | 株式会社カネカ | 細胞膜透過性分子及びその利用、並びに細胞膜透過性分子の細胞膜透過性の向上方法 |
| WO2022065172A1 (ja) * | 2020-09-23 | 2022-03-31 | 株式会社カネカ | 細胞膜透過性分子及びその利用、並びに細胞膜透過性分子の細胞膜透過性の向上方法 |
| WO2022157548A1 (en) | 2021-01-24 | 2022-07-28 | Forrest Michael David | Inhibitors of atp synthase - cosmetic and therapeutic uses |
| US20240368224A1 (en) * | 2021-06-22 | 2024-11-07 | Ohio State Innovation Foundation | Bicyclic peptidyl pan-ras inhibitors |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804558A (en) | 1993-07-20 | 1998-09-08 | University Of California | Protegrins |
| AU758903B2 (en) | 1998-11-26 | 2003-04-03 | Pentapharm Ag | Transport system conjugate |
| US6864355B1 (en) * | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| EP1248642A4 (en) | 2000-01-18 | 2005-05-18 | Ludwig Inst Cancer Res | PEPTIDOMIMETIC INHIBITOR OF VEGF-D / VEGF-C / VEGF |
| US7034109B2 (en) | 2000-10-13 | 2006-04-25 | Christophe Bonny | Intracellular delivery of biological effectors |
| US7033597B2 (en) | 2000-10-13 | 2006-04-25 | Université de Lausanne | Intracellular delivery of biological effectors |
| US7119070B2 (en) * | 2002-04-30 | 2006-10-10 | The Regents Of The University Of California | Antimicrobial theta defensins, analogs thereof, and methods of use |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| US7985401B2 (en) | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| WO2007055578A1 (en) | 2005-11-11 | 2007-05-18 | Leids Universitair Medisch Centrum | Cyclic antimicrobial peptides derived from lactoferrin |
| WO2007069068A2 (en) | 2005-12-16 | 2007-06-21 | Diatos | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
| US20100221235A1 (en) | 2006-02-08 | 2010-09-02 | Diatos | Compositions and Methods for Treating Lysosomal Storage Diseases |
| EP2052011B1 (en) | 2006-08-11 | 2020-11-04 | Starpharma Pty Limited | Targeted polylysine dendrimer therapeutic agent |
| WO2008067026A2 (en) * | 2006-09-29 | 2008-06-05 | Michigan Technological University | Purification of synthetic oligomers |
| WO2008134761A2 (en) | 2007-04-30 | 2008-11-06 | Intezyne Technologies, Inc. | Modification of biological targeting groups for the treatment of cancer |
| DK2257624T5 (da) | 2008-02-05 | 2012-09-10 | Medical Res Council | Fremgangsmåder og sammensætninger |
| US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| GB201016733D0 (en) | 2010-10-05 | 2010-11-17 | Novabiotics Ltd | Compounds and their use |
| SG186347A1 (en) | 2010-06-14 | 2013-01-30 | Hoffmann La Roche | Cell-penetrating peptides and uses therof |
| GB201013980D0 (en) | 2010-08-20 | 2010-10-06 | Ecole Polytech | Bicyclic uPA inhibitors |
| US20140294942A1 (en) | 2011-09-07 | 2014-10-02 | The Regents Of The University Of California | Antiviral peptides effective against hepatitis c virus |
| WO2014053882A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| US10253099B2 (en) | 2012-12-05 | 2019-04-09 | Ruprecht-Karls-Universität Heidelberg | Conjugates of proteins and multivalent cell-penetrating peptides and their uses |
| ES2705068T3 (es) | 2013-05-23 | 2019-03-21 | Ohio State Innovation Foundation | Síntesis química y cribado de bibliotecas de péptidos bicíclicos |
| US10428115B2 (en) | 2013-05-24 | 2019-10-01 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Dynorphin A analogs with bradykinin receptors specificity for modulation of neuropathic pain |
| US20160271216A1 (en) | 2013-08-09 | 2016-09-22 | Apellis Pharmaceuticals, Inc. | Compositions and methods relating to c5l2 |
| CN106103472A (zh) | 2013-10-01 | 2016-11-09 | 哈佛大学的校长及成员们 | 稳定化的多肽及其用途 |
| AU2014331812B2 (en) * | 2013-10-09 | 2019-01-17 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| US10736932B2 (en) | 2014-05-20 | 2020-08-11 | Ohio State Innovation Foundation | Small molecule Ras inhibitors |
| RS59119B1 (sr) | 2014-05-21 | 2019-09-30 | Entrada Therapeutics Inc | Peptidi koji prodiru u ćelije i postupci za njihovo pravljenje i upotrebu |
| US10815276B2 (en) | 2014-05-21 | 2020-10-27 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
| US10316061B2 (en) | 2014-10-02 | 2019-06-11 | Temple University Of The Commonwealth System Of Higher Education | Synthesis of cell penetrating peptides for drug delivery and stem cell applications |
| EP3184541A1 (en) * | 2015-12-23 | 2017-06-28 | Institut Pasteur | Stapled peptide inhibitors of nemo as potential anti-inflammatory and anti-cancer drugs |
| CN110114075B (zh) | 2016-11-09 | 2024-01-12 | 俄亥俄州国家创新基金会 | 含有二硫化物的细胞穿透肽及其制备和使用方法 |
| US11352394B2 (en) | 2016-11-22 | 2022-06-07 | Ohio State Innovation Foundation | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof |
| US10913773B2 (en) | 2016-11-22 | 2021-02-09 | Ohio State Innovation Foundation | Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha |
| TW202500573A (zh) | 2016-11-22 | 2025-01-01 | 俄亥俄州立創新基金會 | 細胞穿透肽序列 |
| CA3078504A1 (en) | 2017-10-04 | 2019-04-11 | Ohio State Innovation Foundation | Bicyclic peptidyl inhibitors |
| US10738093B2 (en) | 2018-01-25 | 2020-08-11 | The Hong Kong University Of Science And Technology | Discovery of cationic nonribosomal peptides as Gram-negative antibiotics through global genome mining |
| WO2019148194A2 (en) | 2018-01-29 | 2019-08-01 | Ohio State Innovation Foundation | Peptidyl inhibitors of calcineurin-nfat interaction |
-
2017
- 2017-11-09 CN CN201780069098.8A patent/CN110114075B/zh active Active
- 2017-11-09 TW TW106138809A patent/TWI781963B/zh active
- 2017-11-09 EP EP17870556.2A patent/EP3538125A4/en active Pending
- 2017-11-09 US US16/348,706 patent/US11351222B2/en active Active
- 2017-11-09 CN CN202410024308.3A patent/CN117866042A/zh active Pending
- 2017-11-09 WO PCT/US2017/060881 patent/WO2018089648A2/en not_active Ceased
- 2017-11-09 CA CA3043464A patent/CA3043464A1/en active Pending
- 2017-11-09 JP JP2019524067A patent/JP7175887B2/ja active Active
-
2021
- 2021-11-30 US US17/538,330 patent/US11878046B2/en active Active
-
2022
- 2022-11-09 JP JP2022179784A patent/JP7490735B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502051A5 (enExample) | ||
| JP2012530145A5 (enExample) | ||
| JP5683951B2 (ja) | 長期間作用性ペプチド類似体のための組成物 | |
| JP2011511753A5 (enExample) | ||
| JP2017534676A5 (enExample) | ||
| JP2006514607A5 (enExample) | ||
| JP6633523B2 (ja) | Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体 | |
| JP2008525491A5 (enExample) | ||
| JP2013518115A5 (enExample) | ||
| JP2012509902A5 (enExample) | ||
| JP2013500990A5 (enExample) | ||
| JP2017522362A5 (enExample) | ||
| WO2006050959A2 (en) | Molecules which promote hematopoiesis | |
| JP2017535527A5 (enExample) | ||
| CN105102470A (zh) | 新型α4β7肽二聚体拮抗剂 | |
| JP2021073174A5 (enExample) | ||
| TW202317604A (zh) | 用於治療遺傳性血鐵沉積症之鐵調素模擬物 | |
| JP2015534972A5 (enExample) | ||
| TW201811817A (zh) | 血小板反應素１結合肽 | |
| KR102057508B1 (ko) | 혈청 인을 조절하는 치료제 | |
| CN106659764A (zh) | 环状鞘脂激活蛋白原肽及其用途 | |
| JPWO2020066343A1 (ja) | 細胞膜透過性ペプチド | |
| JP2005060315A (ja) | 製剤組成物 | |
| JP2012180315A (ja) | タンパク質チロシンキナーゼ阻害活性を有する環状ペプチド化合物 | |
| TW202231655A (zh) | 用於診斷及治療之改良的膽囊收縮素-2受體(cck2r)標靶 |